Filing Details

Accession Number:
0001209191-18-055701
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-19 16:52:36
Reporting Period:
2018-10-19
Accepted Time:
2018-10-19 16:52:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1459839 Si-Bone Inc. SIBN () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
1615374 Orbimed Capital Gp V Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-19 605,964 $0.00 605,964 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-10-19 179,404 $0.00 785,368 No 4 C Indirect By OrbiMed Private Investments V, LP
Common Stock Acquisiton 2018-10-19 200,000 $15.00 985,368 No 4 P Indirect By OrbiMed Private Investments V, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 C Indirect By OrbiMed Private Investments V, LP
No 4 P Indirect By OrbiMed Private Investments V, LP
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series 6 Preferred Stock Disposition 2018-10-19 572,326 $0.00 605,964 $0.00
Common Stock Series 7 Preferred Stock Disposition 2018-10-19 179,404 $0.00 179,404 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The Issuer's Series 6 Preferred Stock automatically converted into approximately 1.05878 shares of Issuer's common stock immediately uponthe closing of the Issuer's initial public offering and has no expiration date.
  2. Shares held by OrbiMed Private Investments V, LP. ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI V and as a result may be deemed to have have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. David P. Bonita, a member of the Issuer's board of directors, is an employee of OrbiMed Advisors.
  3. This report on Form 4 is jointly filed by GP V and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
  4. The Issuer's Series 7 Preferred Stock automatically converted into an equal number of shares of Issuer's common stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.